Form D · Pharmaceuticals

Triana Biomedicines, Inc.

Lexington, MA · CIK 0001815337

Offering snapshot reported Dec 4, 2025 · SEC filing

Reported sold
$120M
Offering amount: $120M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 26, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 4, 2025Initial$120,061,960No comparison20SEC filing
Apr 19, 2022Amendment$42,550,007$7,749,999vs Feb 11, 202214SEC filing
Feb 11, 2022Initial$34,800,008No comparison12SEC filing
Sep 17, 2021Initial$10,000,000No comparison1SEC filing
Jul 6, 2020Initial$6,000,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-565748

Source: Form D, filed Dec 4, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nathaniel Brooks Horwitz Director
Shelley Chu Director
Milind Deshpande Director
David Grayzel Director
Andrew Hedin Director
Lorence Kim Director
Andrew Levin Director
Christopher O'donnel Director
Christopher O'donnell Director
Jigar Raythatha Director
Simon Read Director
Joshua Resnick Director
Patrick Trojer Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1050 Waltham Street Suite 301
Lexington, MA, 02421
Phone: 781-317-4414